Loading…
l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus
Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are acti...
Saved in:
Published in: | Neuropharmacology 2009-09, Vol.57 (4), p.425-429 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93 |
---|---|
cites | |
container_end_page | 429 |
container_issue | 4 |
container_start_page | 425 |
container_title | Neuropharmacology |
container_volume | 57 |
creator | Vámos, Enikő Párdutz, Árpád Varga, Hedvig Bohár, Zsuzsanna Tajti, János Fülöp, Ferenc Toldi, József Vécsei, László |
description | Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl-
d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of
l-kynurenine (
l-KYN) combined with probenecid (PROB) or with 2-(2-
N,
N-dimethylaminoethylamine-1-carbonyl)-1
H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with
l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs. |
doi_str_mv | 10.1016/j.neuropharm.2009.06.033 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21114569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002839080900197X</els_id><sourcerecordid>21114569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EokvpKyCfuCWME8dxjlBBi1TRA71bXnvS9ZI4i_9stY_Dm-LtLuqR09jj75tP4x8hlEHNgIlP29pjDstuo8NcNwBDDaKGtn1FVkz2bdWD4K_JCqCRVTuAvCDvYtwCAJdMviUXbOgkSDasyJ-p-nXwOaB3HqlZ5nWplj65tKG7sKzRo3GWam9p2iD1yx4nGg--XJIz9J_XUH2UWQxur5PbI9Upoc86FY9LYXmcDqY8-sp5m01J8D_uf1Lnn6cGnajR2eqJpuAecXa-HH02E-b4nrwZ9RTx6lwvycO3rw_Xt9Xd_c336893leHAU9WhMFLaEXC0uulHZE2jS4-LTsp-6AfetYxLK1ppO24M4GAtGtHb1qIe2kvy8TS2bP07Y0xqdtHgNGmPS46qYYzxThyF8iQ0YYkx4Kh2wc06HBQDdaSjtuqFjjrSUSBUoVOsH84ZeT2jfTGecRTBl5MAy6J7h0FF49CX_3IBTVJ2cf9P-Qv8hKvx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21114569</pqid></control><display><type>article</type><title>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</title><source>Elsevier</source><creator>Vámos, Enikő ; Párdutz, Árpád ; Varga, Hedvig ; Bohár, Zsuzsanna ; Tajti, János ; Fülöp, Ferenc ; Toldi, József ; Vécsei, László</creator><creatorcontrib>Vámos, Enikő ; Párdutz, Árpád ; Varga, Hedvig ; Bohár, Zsuzsanna ; Tajti, János ; Fülöp, Ferenc ; Toldi, József ; Vécsei, László</creatorcontrib><description>Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl-
d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of
l-kynurenine (
l-KYN) combined with probenecid (PROB) or with 2-(2-
N,
N-dimethylaminoethylamine-1-carbonyl)-1
H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with
l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2009.06.033</identifier><identifier>PMID: 19580819</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject><![CDATA[2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride ; Animals ; Caudal spinal trigeminal nucleus ; Central Nervous System Agents - administration & dosage ; Central Nervous System Agents - pharmacology ; Cervical Vertebrae ; Drug Synergism ; Kynurenic acid ; Kynurenic Acid - analogs & derivatives ; Kynurenic Acid - metabolism ; Kynurenine - administration & dosage ; Kynurenine - pharmacology ; Male ; Neuronal nitric oxide synthase ; Nitric Oxide Donors - administration & dosage ; Nitric Oxide Donors - pharmacology ; Nitric Oxide Synthase Type I - metabolism ; Nitroglycerin ; Nitroglycerin - administration & dosage ; Nitroglycerin - pharmacology ; Probenecid - administration & dosage ; Probenecid - pharmacology ; Quinolones - administration & dosage ; Quinolones - chemistry ; Quinolones - pharmacology ; Rat ; Rats ; Rats, Sprague-Dawley ; Spinal Cord - drug effects ; Spinal Cord - enzymology ; Spinal Cord - metabolism ; Time Factors ; Trigeminal Nuclei - drug effects ; Trigeminal Nuclei - enzymology ; Trigeminal Nuclei - metabolism]]></subject><ispartof>Neuropharmacology, 2009-09, Vol.57 (4), p.425-429</ispartof><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19580819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vámos, Enikő</creatorcontrib><creatorcontrib>Párdutz, Árpád</creatorcontrib><creatorcontrib>Varga, Hedvig</creatorcontrib><creatorcontrib>Bohár, Zsuzsanna</creatorcontrib><creatorcontrib>Tajti, János</creatorcontrib><creatorcontrib>Fülöp, Ferenc</creatorcontrib><creatorcontrib>Toldi, József</creatorcontrib><creatorcontrib>Vécsei, László</creatorcontrib><title>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl-
d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of
l-kynurenine (
l-KYN) combined with probenecid (PROB) or with 2-(2-
N,
N-dimethylaminoethylamine-1-carbonyl)-1
H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with
l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.</description><subject>2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride</subject><subject>Animals</subject><subject>Caudal spinal trigeminal nucleus</subject><subject>Central Nervous System Agents - administration & dosage</subject><subject>Central Nervous System Agents - pharmacology</subject><subject>Cervical Vertebrae</subject><subject>Drug Synergism</subject><subject>Kynurenic acid</subject><subject>Kynurenic Acid - analogs & derivatives</subject><subject>Kynurenic Acid - metabolism</subject><subject>Kynurenine - administration & dosage</subject><subject>Kynurenine - pharmacology</subject><subject>Male</subject><subject>Neuronal nitric oxide synthase</subject><subject>Nitric Oxide Donors - administration & dosage</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Nitric Oxide Synthase Type I - metabolism</subject><subject>Nitroglycerin</subject><subject>Nitroglycerin - administration & dosage</subject><subject>Nitroglycerin - pharmacology</subject><subject>Probenecid - administration & dosage</subject><subject>Probenecid - pharmacology</subject><subject>Quinolones - administration & dosage</subject><subject>Quinolones - chemistry</subject><subject>Quinolones - pharmacology</subject><subject>Rat</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Spinal Cord - drug effects</subject><subject>Spinal Cord - enzymology</subject><subject>Spinal Cord - metabolism</subject><subject>Time Factors</subject><subject>Trigeminal Nuclei - drug effects</subject><subject>Trigeminal Nuclei - enzymology</subject><subject>Trigeminal Nuclei - metabolism</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxi0EokvpKyCfuCWME8dxjlBBi1TRA71bXnvS9ZI4i_9stY_Dm-LtLuqR09jj75tP4x8hlEHNgIlP29pjDstuo8NcNwBDDaKGtn1FVkz2bdWD4K_JCqCRVTuAvCDvYtwCAJdMviUXbOgkSDasyJ-p-nXwOaB3HqlZ5nWplj65tKG7sKzRo3GWam9p2iD1yx4nGg--XJIz9J_XUH2UWQxur5PbI9Upoc86FY9LYXmcDqY8-sp5m01J8D_uf1Lnn6cGnajR2eqJpuAecXa-HH02E-b4nrwZ9RTx6lwvycO3rw_Xt9Xd_c336893leHAU9WhMFLaEXC0uulHZE2jS4-LTsp-6AfetYxLK1ppO24M4GAtGtHb1qIe2kvy8TS2bP07Y0xqdtHgNGmPS46qYYzxThyF8iQ0YYkx4Kh2wc06HBQDdaSjtuqFjjrSUSBUoVOsH84ZeT2jfTGecRTBl5MAy6J7h0FF49CX_3IBTVJ2cf9P-Qv8hKvx</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Vámos, Enikő</creator><creator>Párdutz, Árpád</creator><creator>Varga, Hedvig</creator><creator>Bohár, Zsuzsanna</creator><creator>Tajti, János</creator><creator>Fülöp, Ferenc</creator><creator>Toldi, József</creator><creator>Vécsei, László</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20090901</creationdate><title>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</title><author>Vámos, Enikő ; Párdutz, Árpád ; Varga, Hedvig ; Bohár, Zsuzsanna ; Tajti, János ; Fülöp, Ferenc ; Toldi, József ; Vécsei, László</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride</topic><topic>Animals</topic><topic>Caudal spinal trigeminal nucleus</topic><topic>Central Nervous System Agents - administration & dosage</topic><topic>Central Nervous System Agents - pharmacology</topic><topic>Cervical Vertebrae</topic><topic>Drug Synergism</topic><topic>Kynurenic acid</topic><topic>Kynurenic Acid - analogs & derivatives</topic><topic>Kynurenic Acid - metabolism</topic><topic>Kynurenine - administration & dosage</topic><topic>Kynurenine - pharmacology</topic><topic>Male</topic><topic>Neuronal nitric oxide synthase</topic><topic>Nitric Oxide Donors - administration & dosage</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Nitric Oxide Synthase Type I - metabolism</topic><topic>Nitroglycerin</topic><topic>Nitroglycerin - administration & dosage</topic><topic>Nitroglycerin - pharmacology</topic><topic>Probenecid - administration & dosage</topic><topic>Probenecid - pharmacology</topic><topic>Quinolones - administration & dosage</topic><topic>Quinolones - chemistry</topic><topic>Quinolones - pharmacology</topic><topic>Rat</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Spinal Cord - drug effects</topic><topic>Spinal Cord - enzymology</topic><topic>Spinal Cord - metabolism</topic><topic>Time Factors</topic><topic>Trigeminal Nuclei - drug effects</topic><topic>Trigeminal Nuclei - enzymology</topic><topic>Trigeminal Nuclei - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vámos, Enikő</creatorcontrib><creatorcontrib>Párdutz, Árpád</creatorcontrib><creatorcontrib>Varga, Hedvig</creatorcontrib><creatorcontrib>Bohár, Zsuzsanna</creatorcontrib><creatorcontrib>Tajti, János</creatorcontrib><creatorcontrib>Fülöp, Ferenc</creatorcontrib><creatorcontrib>Toldi, József</creatorcontrib><creatorcontrib>Vécsei, László</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vámos, Enikő</au><au>Párdutz, Árpád</au><au>Varga, Hedvig</au><au>Bohár, Zsuzsanna</au><au>Tajti, János</au><au>Fülöp, Ferenc</au><au>Toldi, József</au><au>Vécsei, László</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>57</volume><issue>4</issue><spage>425</spage><epage>429</epage><pages>425-429</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl-
d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of
l-kynurenine (
l-KYN) combined with probenecid (PROB) or with 2-(2-
N,
N-dimethylaminoethylamine-1-carbonyl)-1
H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with
l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>19580819</pmid><doi>10.1016/j.neuropharm.2009.06.033</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3908 |
ispartof | Neuropharmacology, 2009-09, Vol.57 (4), p.425-429 |
issn | 0028-3908 1873-7064 |
language | eng |
recordid | cdi_proquest_miscellaneous_21114569 |
source | Elsevier |
subjects | 2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride Animals Caudal spinal trigeminal nucleus Central Nervous System Agents - administration & dosage Central Nervous System Agents - pharmacology Cervical Vertebrae Drug Synergism Kynurenic acid Kynurenic Acid - analogs & derivatives Kynurenic Acid - metabolism Kynurenine - administration & dosage Kynurenine - pharmacology Male Neuronal nitric oxide synthase Nitric Oxide Donors - administration & dosage Nitric Oxide Donors - pharmacology Nitric Oxide Synthase Type I - metabolism Nitroglycerin Nitroglycerin - administration & dosage Nitroglycerin - pharmacology Probenecid - administration & dosage Probenecid - pharmacology Quinolones - administration & dosage Quinolones - chemistry Quinolones - pharmacology Rat Rats Rats, Sprague-Dawley Spinal Cord - drug effects Spinal Cord - enzymology Spinal Cord - metabolism Time Factors Trigeminal Nuclei - drug effects Trigeminal Nuclei - enzymology Trigeminal Nuclei - metabolism |
title | l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A23%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=l-kynurenine%20combined%20with%20probenecid%20and%20the%20novel%20synthetic%20kynurenic%20acid%20derivative%20attenuate%20nitroglycerin-induced%20nNOS%20in%20the%20rat%20caudal%20trigeminal%20nucleus&rft.jtitle=Neuropharmacology&rft.au=V%C3%A1mos,%20Enik%C5%91&rft.date=2009-09-01&rft.volume=57&rft.issue=4&rft.spage=425&rft.epage=429&rft.pages=425-429&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2009.06.033&rft_dat=%3Cproquest_cross%3E21114569%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21114569&rft_id=info:pmid/19580819&rfr_iscdi=true |